Search research articles
Contact Us
Filters
Showing results (21-30 of 99) with videos related to
Page
of 10
Sort By:
Gynecologic Oncology
|
December 1, 1990
A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study
G R Weiss, S Green, E V Hannigan, et al.
Gynecologic Oncology
|
June 1, 1992
A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: a Southwest Oncology Group trial
G R Weiss, P Y Liu, J O'Sullivan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 21, 2004
NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen
L A deGraffenried, B Chandrasekar, W E Friedrichs, et al.
Gynecologic Oncology
|
June 1, 1990
A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial
G R Weiss, S Green, E V Hannigan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1984
Pulmonary uptake of technetium 99m macroaggregated albumin: a predictor of gastrointestinal toxicity during hepatic artery perfusion
W D Kaplan, S E Come, R W Takvorian, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1985
A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer
G R Weiss, M Hersh, J G Kuhn, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
January 1, 1991
New anticancer agents
T D Brown, H A Burris, K A Havlin, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
May 9, 2000
New anticancer agents
C Britten, L Hammond, M Hidalgo, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
January 1, 1992
New anticancer agents
T D Brown, H A Burris, J R Eckardt, et al.
Cancer
|
February 1, 1995
A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study
W S Dalton, J J Crowley, S S Salmon, et al.
Page
of 10
Search research articles
Search
Showing results (21-30 of 99) with videos related to
Sort By:
Page
of 10
Gynecologic Oncology
|
December 1, 1990
A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study
G R Weiss, S Green, E V Hannigan, et al.
Gynecologic Oncology
|
June 1, 1992
A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: a Southwest Oncology Group trial
G R Weiss, P Y Liu, J O'Sullivan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 21, 2004
NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen
L A deGraffenried, B Chandrasekar, W E Friedrichs, et al.
Gynecologic Oncology
|
June 1, 1990
A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial
G R Weiss, S Green, E V Hannigan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1984
Pulmonary uptake of technetium 99m macroaggregated albumin: a predictor of gastrointestinal toxicity during hepatic artery perfusion
W D Kaplan, S E Come, R W Takvorian, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1985
A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer
G R Weiss, M Hersh, J G Kuhn, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
January 1, 1991
New anticancer agents
T D Brown, H A Burris, K A Havlin, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
May 9, 2000
New anticancer agents
C Britten, L Hammond, M Hidalgo, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
January 1, 1992
New anticancer agents
T D Brown, H A Burris, J R Eckardt, et al.
Cancer
|
February 1, 1995
A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study
W S Dalton, J J Crowley, S S Salmon, et al.
Page
of 10